We are part of the CSL Limited group of companies. See how we're Driven by Our Promise.
We collaborate with rare disease organizations to promote quality medical care and services.
We offer a variety of support programs and activities for the patients we serve.
We also aim to make sure that nothing holds you back from getting the therapies you need.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise.
A clinical trial is a research study that is done to find out if medical treatments can improve people’s health.
We work every day as if someone’s life depends on it, because it does.
We manufacture products to treat a number of rare diseases.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL Behring.
Using AI and Data Science
With artificial intelligence, “we can get there faster, evaluate faster and relaunch faster when needed.”
Video: Innovation in Marburg, Germany
CSL Behring’s largest R&D and manufacturing site is in this university town, where game-changing science is happening.
Together, Let's Move at the Speed of Science
A condensed version of my address to academia, governments and industry during the Times Higher Education Health and Wellbein…
Biotech Firms Respond to IP Debate
Hundreds of CEOs sign a joint statement, saying IP “created the biotech network that responded so quickly to the COVID crisis…
At the Heart of Innovation for Patients
Marburg, Germany’s vibrant R&D ecosystem creates hope for patients and CSL Behring’s future.
A Research Catalyst in Switzerland
A new partnership between CSL Behring and Biopôle takes shape, pairing the global biotech with one of the most dynamic life s…
The Fight Against COVID-19
Two CSL leaders talk with BioSpace.com about the company’s ongoing work all over the world.
Australia's “60 Minutes” Reports on CSL & COVID-19
About producing AstraZeneca's COVID-19 vaccine, Seqirus leader says: “I’m just incredibly proud that we can play such an impo…
G'Day USA
CEO Paul Perreault discusses COVID-19 medical innovation with health care leaders from US and Australia.
Protecting Public Health During a Pandemic
A leader with Seqirus, a major flu vaccine producer, talks about the twin threats of influenza and COVID-19.
Three Rules for a Post-COVID World
“We’re all disrupters now,” says futurist Mike Walsh, who addressed 500 CSL leaders on 2021 and what comes next.
Industry Partnership Fuels Research, Advocacy
PhRMA membership expands CSL Behring’s opportunity for cooperation between industry leaders.
Popular search terms:
Americas
Asia Pacific
Europe
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
